Liquid biopsy of pancreatic tumors: Challenges for early detection and surveillance based on the molecular landscape during early carcinogenesis

DOI Web Site 1 Citations 57 References
  • OKADA Tetsuhiro
    Division of Gastroenterology and Hematology/Oncology, Department of Medicine, Asahikawa Medical University Department of Gastroenterology, Asahikawa Kosei Hospital
  • MIZUKAMI Yusuke
    Division of Gastroenterology and Hematology/Oncology, Department of Medicine, Asahikawa Medical University Institute of Biomedical Research, Sapporo Higashi Tokushukai Hospital
  • HAYASHI Akihiro
    Division of Gastroenterology and Hematology/Oncology, Department of Medicine, Asahikawa Medical University
  • KAWABATA Hidemasa
    Division of Gastroenterology and Hematology/Oncology, Department of Medicine, Asahikawa Medical University
  • SATO Hiroki
    Division of Gastroenterology and Hematology/Oncology, Department of Medicine, Asahikawa Medical University
  • KAWAMOTO Toru
    Department of Gastroenterology, Asahikawa Kosei Hospital
  • GOTO Takuma
    Division of Gastroenterology and Hematology/Oncology, Department of Medicine, Asahikawa Medical University
  • TANIUE Kenzui
    Institute of Biomedical Research, Sapporo Higashi Tokushukai Hospital
  • ONO Yusuke
    Division of Gastroenterology and Hematology/Oncology, Department of Medicine, Asahikawa Medical University Institute of Biomedical Research, Sapporo Higashi Tokushukai Hospital
  • KARASAKI Hidenori
    Institute of Biomedical Research, Sapporo Higashi Tokushukai Hospital
  • OKUMURA Toshikatsu
    Division of Gastroenterology and Hematology/Oncology, Department of Medicine, Asahikawa Medical University

Bibliographic Information

Other Title
  • 膵癌の初期発生とリキッドバイオプシーによる分子診断

Abstract

<p>Comprehensive studies of the pancreatic cancer genome have revealed that most genetic alterations are associated with specific core signaling pathways, and these are driven by the KRAS, CDKN2A, TP53, and SMAD4 genes that are frequently mutated as well as several low-frequency mutated genes. In addition to these mutations, other molecular abnormalities that include variations in gene expression, protein levels, and metabolic markers may be applied as new diagnostic tools for pancreatic cancer. Liquid biopsy-based molecular testing that reflects intratumor heterogeneity can be used not only for selecting smart drugs for advanced cancers but also as a tool to identify early-stage disease and screen individuals at high-risk. To apply these detailed molecular profiles in precision medicine, it is crucial to understand the biological features of tumor pathogenesis including the presence of multicentric lesions in the pancreas, intra-tumor heterogeneity, and their clonal evolution. This review outlines the molecular abnormalities that occur during the early development of pancreatic cancer and introduces the latest innovative technologies that may be relevant to clinical practice.</p>

Journal

  • Suizo

    Suizo 35 (4), 302-312, 2020-08-31

    Japan Pancreas Society

Citations (1)*help

See more

References(57)*help

See more

Related Projects

See more

Keywords

Details 詳細情報について

Report a problem

Back to top